|Table 3: Bispyribac-sodium, imazamox, and penoxsulam dose required to kill 50% (LD50) and 90% (LD90) of ALS-resistant (AR1, AR2, and MS1) and -susceptible E. crus-galli populations (with 95% CI in parenthesis)a,b,c,d.|
aLD50 and LD90 were determined by conducting Probit analysis in SAS.|
bR/S ratio was calculated by dividing the LD50 and LD90 dose of resistant population by the LD50 and LD90 dose, respectively, of susceptible population.
cAll imazamox and penoxsulam treatments contained a nonionic surfactant at 0.25% v/v.
dBispyribac-sodium treatments contained a nonionic spray adjuvant and deposition aid at 2.5% v/v.